Kaplan-Meier plots for the impact on PFS of different plasma DNA-based biomarkers. Plasma DNA concentration measure with (A) Qubit, (B) DNA prop and (C) 20% increase in ACTBshort between baseline and evaluation one. No significant impact was observed on PFS for (A) the plasma DNA concentration, (B) whereas a ≥ 70% DNA prop and (C) a ≥ 20% increase in ACTBshort had an unfavorable prognostic impact. DNA prop, DNA proportion; HR, hazard ratio; PFS, progression-free survival.